Fetal Aortic Valvuloplasty for Congenital Heart Disease

This observational study is looking at the effect of fetal aortic balloon dilatation (a procedure where a balloon is used to widen a narrowed aortic valve before birth) on babies born with certain heart conditions. Specifically, it aims to see if this procedure can reduce the risk of a baby developing hypoplastic left heart syndrome (HLHS), a severe condition where the left side of the heart is underdeveloped. Researchers will also investigate if the treatment improves the baby's overall prognosis. You might be able to participate if you are between 23 and 31 weeks pregnant and your baby meets specific heart ultrasound criteria, including a narrowed aortic valve with forward blood flow. The main goal is to see if babies who have this procedure have a better chance of surviving without needing a heart transplant by two years of age. The study status is currently unclear.

Study design
This is an observational study with a planned enrollment of 200 participants. It compares the outcomes of babies who receive fetal aortic balloon dilatation to those who do not.
What's involved
Participation involves routinely collected pre- and postnatal clinical data and echocardiographic examinations. The number of examinations is not different from standard care.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from study inclusion during fetal life until 2 years postnatal age.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05386173

Effect of Fetal Aortic Valvuloplasty on Outcomes

Recruiting
Not specifiedAges 23–31Observational
Queen Silvia Children's Hospital, Gothenburg, Sweden
~200 participants
Updated 2025-03-21 on ClinicalTrials.gov
What's tested:Fetal aortic balloon dilatation

At a glance

Recruiting sites
13 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Transplantation-free survival
Measured over Follow-up from study inclusion during fetal life until 2 years postnatal age
Congenital Heart Disease
Aortic Valve Stenosis
Fetal Cardiac Disorder
Hypoplastic Left Heart Syndrome
13 sites across 9 states
Germany3
Sweden3
California1
Ohio1
Austria1
Canada1
Finland1
Poland1

Opens a ready-to-send draft in your own email app — review before sending.

  • Transplantation-free survivalFollow-up from study inclusion during fetal life until 2 years postnatal age

    Transplantation-free survival from fetal diagnosis to 2 years postnatal age with a biventricular circulation without pulmonary hypertension at that time. Absence of pulmonary hypertension is defined as a TR max velocity ≤ 2.8 m/s with no other echocardiographic signs of pulmonary hypertension and/or catheter data showing a mean pulmonary arterial pressure \<25 mmHg.